Our analysis also incorporated the beneficial effects of blood pressure reduction and recent CKD treatment improvements, including the effect of SGLT2 inhibitors that have shown their kidney- and cardioprotective effect in addition to RAS inhibition. Here, SLC5A2 is linked to chronic kidney disease.